Plus Therapeutics (PSTV) said Monday that data from an early-stage trial using Reyobiq to treat leptomeningeal metastases, a kind of cancer, is "feasible, has a manageable safety profile, and shows a promising efficacy signal."
The study involved 29 patients in six cohorts who received a different dosage in each one, the company said.
The company said that the trial data showed a radiographic and clinical response rate of 76% and 87%, respectively, through day 112, that CSF tumor cell enumeration assays had a maximum reduction over baseline of 100% at day 28, and that five of the seven patients with a TCE response of more than 80% survived for at least one year.
Shares of Plus Therapeutics were down 3% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.